Multimodal Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma -ECF vs. FLOT

被引：0
|
作者：
Schroeder, W. [1 ]
Bruns, C. J. [1 ]
机构：
[1] Univ Klin Koln, Klin Allgemein Viszeral & Tumorchirurg, Kerpener Str 62, D-50937 Cologne, Germany
来源：
CHIRURG | 2019年 / 90卷
关键词：
D O I：
10.1007/s00104-019-0841-4
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [1] Multimodal Therapy for Gastric Carcinoma and gastroesophageal junction Adenocarcinoma - ECF vs. FLOT
    Schroeder, W.
    Bruns, C. J.
    CHIRURG, 2017, 88 (06): : 540 - 540
  • [2] Multimodale Therapie des Magenkarzinoms und Karzinoms des gastroösophagealen Übergangs – ECF vs. FLOTMultimodal therapy for gastric or gastroesophageal junction adenocarcinoma —ECF vs. FLOT
    W. Schröder
    C. J. Bruns
    Der Chirurg, 2019, 90 (Suppl 2): : 27 - 27
  • [3] Multimodale Therapie des Magenkarzinoms und Karzinoms des gastroösophagealen Übergangs – ECF vs. FLOTMultimodal therapy for gastric or gastroesophageal junction adenocarcinoma —ECF vs. FLOT
    W. Schröder
    C. J. Bruns
    Der Chirurg, 2017, 88 (6): : 540 - 540
  • [4] Response to neoadjuvant chemotherapy in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma with FLOT-regimen in our setting
    Garcia Grove, C.
    Gallego Jimenez, I.
    Martinez Bernal, G.
    Miras Rodriguez, I.
    Limon Miron, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S119 - S119
  • [5] Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4): A multice
    Moenig, St.
    Al-Batran, S. E.
    BRITISH JOURNAL OF SURGERY, 2018, 105 : 19 - 20
  • [6] Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma
    Zeng, Hanqing
    Wang, Chunjiang
    Song, Li-Ying
    Jia, Su-Jie
    Zeng, Xiaohui
    Liu, Qiao
    BMJ OPEN, 2022, 12 (11):
  • [7] Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma
    Shitara, Kohei
    Shah, Manish A.
    Lordick, Florian
    Van Cutsem, Eric
    Ilson, David H.
    Klempner, Samuel J.
    Kang, Yoon-Koo
    Lonardi, Sara
    Hung, Yi-Ping
    Yamaguchi, Kensei
    Enzinger, Peter
    Nakajima, Tomoko
    Matsangou, Maria
    Cao, Ying
    Li, Ran
    Moran, Diarmuid
    Pophale, Rupesh
    Oh, Mok
    Ranganath, Radhika
    Ajani, Jaffer A.
    Xu, Rui-Hua
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (12): : 1160 - +
  • [8] Impact of neoadjuvant FLOT treatment of advanced gastric and gastroesophageal junction cancer following surgical therapy
    Paszt, Attila
    Simonka, Zsolt
    Budai, Krisztina
    Horvath, Zoltan
    Erdos, Marton
    Vas, Marton
    Ottlakan, Aurel
    Nyari, Tibor
    Szepes, Zoltan
    Uhercsak, Gabriella
    Maraz, Aniko
    Torday, Laszlo
    Tiszlavicz, Laszlo
    Olah, Judit
    Lazar, Gyorgy
    FRONTIERS IN SURGERY, 2023, 10
  • [9] Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Li Ning
    Li Zhi
    Fu Qiang
    Zhang Bin
    Zhang Jian
    Wan XiangBin
    Lu Chaomin
    Wang Jinbang
    Deng Wenying
    Wei Chen
    Ma Yijie
    Bie Liangyu
    Wang Mengyu
    Luo Suxia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [10] Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Li, N.
    Li, Z.
    Fu, Q.
    Zhang, B.
    Zhang, J.
    Wan, X.
    Lu, C.
    Wang, J.
    Deng, W.
    Wei, C.
    Ma, Y.
    Bie, L.
    Wang, M.
    Luo, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S1302 - S1302
12345